Source comparison
Stacking LL-37 BPC-157 Chronic Infection: Comparison Table
Before combining peptides, understand how their mechanisms, administration routes, and documented evidence differ. And where they overlap to create synergistic effects. LL-37 Direct antimicrobial via membrane disruption; immune cell chemotaxis via FPRL1 recept
This comparison does not assign a generated winner or score.
- Before combining peptides, understand how their mechanisms, administration routes, and documented evidence differ. And where they overlap to create synergistic effects.
- LL-37
- Direct antimicrobial via membrane disruption; immune cell chemotaxis via FPRL1 receptor binding
- Subcutaneous injection; typical research dose 200–500 mcg/day; topical formulations 0.1–1.0 mg/mL
- In vitro efficacy against MRSA, P. aeruginosa, C. albicans; Phase I safety trials completed; human wound healing data limited to observational studies
- Strong antimicrobial profile but limited by poor tissue penetration in compromised vascular environments. Efficacy drops significantly in chronic infection contexts without concurrent angiogenic support
- BPC-157
- Angiogenesis via VEGF upregulation; anti-inflammatory via TNF-α/NF-κB inhibition; gastric mucosal protection
- Subcutaneous or intramuscular injection; typical research dose 250–500 mcg/day; oral administration possible but bioavailability reduced
- Rodent models show accelerated wound healing, tendon repair, GI tract protection; human clinical trials not yet published; mechanism well-characterized in preclinical models
- Potent tissue repair and vascular restoration effects, but lacks direct antimicrobial action. Addresses infection environment rather than pathogen load itself
- Combined Stack
- Dual pathway: antimicrobial + angiogenic + anti-inflammatory
- Both peptides administered subcutaneously at separate injection sites; timing can be concurrent or staggered within same day
- Synergistic biofilm reduction (73% vs 31% monotherapy) demonstrated in vitro; no published human trials on combined protocols; mechanism supports additive effects
- Mechanistically rational combination for chronic infection where tissue damage and biofilm formation limit single-agent efficacy. Addresses both pathogen clearance and environmental restoration